Nuvectis Pharma, Inc. (NVCT): Targeting High-Unmet Cancer Needs

With early clinical programs showing promise and differentiated targets, this company is drawing attention from both retail traders and institutional biotech watchers.

Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for difficult-to-treat cancers. Its lead candidate, NXP800, is currently in clinical trials for treating advanced solid tumors, including ovarian cancer. Another key asset, NXP900, is in preclinical development and targets SRC/YE…